GlassScriptPhysician profile
Christina A Michael
NPI 1346409463
$9,909.78
in general payments reported to CMS, 2019-2025
31 companies · $1,353 in 2025
The $1,353 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,445 · 2020: $1,359 · 2021: $1,623 · 2022: $1,580 · 2023: $1,409 · 2024: $1,141 · 2025: $1,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,902.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,344.37 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $1,314.33 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $978.07 | 2019-2025 | Farxiga, Brilinta |
| Novartis Pharmaceuticals Corporation | $775.36 | 2019-2025 | |
| Abbott Laboratories | $707.19 | 2019-2025 | Amplatzer Amulet |
| Boston Scientific Corporation | $686.49 | 2019-2025 | Watchman Flx, Farapulse, Bodyguardian |
| Boehringer Ingelheim Pharmaceuticals, INC. | $660.11 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $583.66 | 2021-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $465.86 | 2019-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $447.76 | 2021-2025 | Nexletol |
| Novo Nordisk INC | $303.90 | 2021-2025 | Wegovy, Ozempic |
| Amarin Pharma, INC. | $243.79 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $195.75 | 2021-2024 | |
| Pfizer INC. | $182.44 | 2020-2024 | |
| Cvrx, INC. | $135.82 | 2022-2025 | Barostim Neo System |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $130.33 | 2023-2025 | |
| Heartflow, INC. | $122.75 | 2022 | |
| Medtronic, INC. | $94.39 | 2022-2024 | Micra |
| Philips North America LLC | $90.57 | 2022 | |
| Edwards Lifesciences Corporation | $78.76 | 2025 | Evoque |
| Lilly USA, LLC | $66.93 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Regeneron Healthcare Solutions, INC. | $49.22 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $39.33 | 2019 | |
| Atricure, INC. | $32.04 | 2023 | |
| Biosense Webster, INC. | $30.29 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $29.71 | 2024 | Arcalyst |
| Lundbeck LLC | $29.70 | 2019 | |
| Braemar Manufacturing, LLC | $28.53 | 2019 | |
| Bardy Diagnostics, INC. | $28.00 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $17.92 | 2019 | |
| Medtronic Vascular, INC. | $16.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Michael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.